文献速递消化道肿瘤与早癌消化内镜

林奇综合征主动识别及后续结肠镜监测的成本效益

Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-10-17

加拿大安大略省考虑对70岁以下新诊断结直肠癌患者行免疫组化及级联检测以识别林奇综合征,并评估检测成本效益及一级亲属最佳监测间隔。采用患者流图结合MISCAN-colon模型分析,发现检测1000例结直肠癌可识别20例索引病例和29例林奇综合征一级亲属,成本310,274美元;对一级亲属行每2年结肠镜监测相比常规10年筛查更具成本效益(每获得生命年8785美元),生命年增加122%且节省结直肠癌治疗费用,每3年监测成本更高效果更差,每年监测额外获益有限。

要点

  • 对70岁以下结直肠癌患者行免疫组化及级联检测可有效识别林奇综合征。
  • 林奇综合征一级亲属每2年结肠镜监测是最优策略,成本效益良好。
  • 每3年监测成本更高效果更差,每年监测额外获益有限。

核心结论

  • 对70岁以下结直肠癌患者行免疫组化检测并对其林奇综合征一级亲属行每2年结肠镜监测,在成本与长期获益间取得良好平衡。

研究设计与样本

  • 基于患者流图估算免疫组化检测及级联检测的成本与检出率,并考虑实际接受率。
  • 采用MISCAN-colon模型比较林奇综合征一级亲属每年、每2年、每3年结肠镜监测与每10年常规筛查的成本效益。

主要发现

  • 检测1000例结直肠癌预计识别20例结直肠癌索引病例和29例林奇综合征一级亲属,成本310,274美元。
  • 对林奇综合征一级亲属行每2年结肠镜监测相比常规每10年筛查,每获得生命年成本8785美元,生命年增加122%且节省结直肠癌治疗费用。
  • 每3年监测成本更高且效果更差,每年监测相比每2年监测额外获益有限。

关键数值与推荐

  • 检测1000例结直肠癌识别20例索引病例和29例一级亲属,成本310,274美元。
  • 每2年结肠镜监测成本效益比为每生命年8785美元,生命年增加122%。

临床怎么用

  • 可考虑对70岁以下新诊断结直肠癌患者行免疫组化检测以识别林奇综合征。
  • 对检出的林奇综合征一级亲属推荐每2年结肠镜监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The province of Ontario, Canada is considering immunohistochemical followed by cascade analyses of all patients who received a diagnosis of colorectal cancer (CRC) at an age younger than 70 years to identify individuals with Lynch syndrome. We evaluated the costs and benefits of testing for Lynch syndrome and determined the optimal surveillance interval for first-degree relatives (FDRs) found to have Lynch syndrome. METHODS: We developed a patient flow diagram to determine costs and yield of immunohistochemical testing for Lynch syndrome in CRC cases and, for those found to have Lynch syndrome, their FDRs, accounting for realistic uptake. Subsequently, we used the MISCAN-colon model to compare costs and benefits of annual, biennial, and triennial surveillance in FDRs identified with Lynch syndrome vs colonoscopy screening every 10 years (usual care for individuals without a diagnosis of Lynch syndrome). RESULTS: Testing 1000 CRC cases was estimated to identify 20 CRC index cases and 29 FDRs with Lynch syndrome at a cost of $310,274. Despite the high cost of Lynch syndrome tests, offering the FDRs with Lynch syndrome biennial colonoscopy surveillance was cost-effective at $8785 per life-year gained compared with usual care because of a substantial increase in life-years gained (+122%) and cost savings in CRC care. Triennial surveillance was more costly and less effective, and annual surveillance showed limited additional benefit compared with biennial surveillance. CONCLUSIONS: Immunohistochemical testing for Lynch syndrome in persons younger than 70 years who received a diagnosis of CRC and then testing FDRs of those found to have Lynch syndrome provide a good balance between costs and long-term benefits. Colonoscopy surveillance every 2 years is the optimal surveillance interval for patients with Lynch syndrome.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Peterse EFP, Naber SK, Daly C, et al. Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases. Clin Gastroenterol Hepatol. 2019. PMID: 31629885. doi:10.1016/j.cgh.2019.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。